| PAD negative (P0) (N = 206) | PAD4 Ab only (P4) (N = 34) | PAD3/4 Ab (XR) (N = 34) | p-value P0 vs P4 | p-value P0 vs XR | p-value P4 vs XR |
---|---|---|---|---|---|---|
Female sex- N (%) | 163 (79%) | 27 (79%) | 28 (82%) | 0.99 | 0.66 | 0.76 |
Race- N (%) | Â | Â | Â | 0.99 | 0.91 | 0.95 |
 Caucasian | 165 (80%) | 28 (82.4%) | 27 (79%) |  |  |  |
 African American | 27 (13%) | 4 (11.8%) | 4 (12%) |  |  |  |
 Asian/Other | 14 (7%) | 2 (6%) | 3 (9%) |  |  |  |
Age- median (IQR) | 57 (49–66) | 55 (47–68) | 51.5 (46–64) | 0.70 | 0.14 | 0.33 |
Disease duration (yrs) - median (IQR) | 6 (2–12) | 15.5 (8–27) | 15.5 (7–26) | < 0.01 | < 0.01 | 0.77 |
Ever smoking- N (%) | 95 (47%) | 16 (47%) | 12 (35%) | 0.96 | 0.22 | 0.32 |
Current smoking- N (%) | 24 (12%) | 3 (8.8%) | 0 (0%) | 0.62 | 0.04 | 0.08 |
CCP positive- N (%) | 116 (57%) | 30 (88.2%) | 30 (88.2%) | < 0.01 | < 0.01 | 1.0 |
Shared Epitope- N (%) | 112 (54%) | 28 (82.4%) | 22 (64.7%) | < 0.01 | 0.26 | 0.10 |
Erosions- N (%) N = 268 | 88 (43%) | 17 (54.8%) | 22 (65%) | 0.24 | 0.02 | 0.42 |
CDAI- median (IQR) | 7.9 (3–16) | 7 (2.8–11.5) | 3.7 (1.5–9.5) | 0.37 | 0.04 | 0.21 |
On a DMARD- N (%) | 184 (90%) | 28 (82%) | 28 (82%) | 0.21 | 0.20 | 1.0 |
On methotrexate- N (%) | 127 (63%) | 20 (59%) | 24 (71%) | 0.73 | 0.33 | 0.31 |
On a biologic- N (%) | 89 (44%) | 17 (50%) | 16 (47%) | 0.49 | 0.71 | 0.81 |